

## CONTENTS

	Page
ACKNOWLEDGEMENTS.....	i
ABSTRACT.....	iii
ABSTRAK.....	vii
CONTENT.....	xi
LIST OF FIGURES.....	xvi
LIST OF TABLES.....	xvii
<b>CHAPTER 1: INTRODUCTION</b>	
1.1 The Immune System.....	1
1.1.1 The Innate Immune System.....	1
1.1.2 The Adaptive Immune System.....	2
1.2 The B Cells.....	4
1.3 The T Cells.....	11
1.3.1 T Cell Function.....	11
1.3.2 The T Cell Receptors.....	14
1.3.2.1 Identification of the Alpha-Beta T Cell Receptor.....	14
1.3.2.2 Architecture of the Alpha-Beta Heterodimer..	15
1.3.2.3 Identification of the Gamma-Delta T Cell Receptor.....	21
1.3.2.4 Architecture of the Gamma-Delta Heterodimer.	23
1.3.2.5 Somatic Rearrangement of Gene Elements.....	25
1.3.3 T Cell Maturation.....	28
1.3.3.1 T Cell Leukaemia.....	28
1.3.3.2 T Cell Ontogeny.....	28

1.3.3.2.1	Surface Markers.....	29
1.3.3.2.2	Gene Rearrangement.....	30
1.3.3.3	Adult Thymus.....	33
1.3.3.4	Blood and Peripheral Organs.....	35
1.3.4	T Cell Maturation in Human.....	37
1.3.5	Diversity of T Cell Receptors.....	40
1.3.6	Are TCR Gamma-Delta and TCR Alpha-Beta of the Same Lineage.....	42
1.3.7	Extrathymic T Cell Differentiation.....	44
1.3.8	T Cell Recognition.....	45
1.3.9	Thymic Selection.....	48
1.3.10	Thymic Hormones.....	50
1.3.11	The Ig Superfamily.....	50
1.4	Neoplasm of the Immune System.....	51
1.4.1	Leukaemias.....	51
1.4.1.1	Acute Leukaemias.....	52
1.4.1.2	Chronic Leukaemias.....	54
1.4.2	Malignant Lymphomas.....	55
1.4.2.1	Hodgkin's Disease.....	55
1.4.2.2	Non-Hodgkin's Lymphoma.....	55
1.5	Diagnosis.....	57
1.5.1	Morphological Studies.....	57
1.5.2	Cytochemistry.....	59
1.5.3	Immunophenotyping.....	60
1.5.3.1	Clusters of Differentiation.....	65
1.5.4	Gene Rearrangement Studies and mRNA Expression.....	67

1.5.4.1	Gene Segment Usage in Leukaemia Cells.....	70
1.5.5	Cytogenetics.....	73
1.5.6	TCR Protein Expression.....	74
1.6	Treatment.....	75
1.7	Objectives of Research.....	79
<b>CHAPTER 2: MATERIALS AND METHODS</b>		
A.	Immunophenotyping.....	80
2.1	Materials.....	80
2.1.1	Bone Marrow and Blood Source.....	80
2.1.2	Chemicals and Reagents.....	80
2.1.3	Preparation of Solution.....	81
2.2	Method.....	82
2.2.1	Immunoperoxidase.....	82
2.2.2	Sample Collection.....	83
2.2.3	Mononuclear Layer Separation.....	84
2.2.4	Cell Count.....	84
2.2.5	Cryopreservation.....	85
2.2.6	Viability Test.....	86
2.2.7	Blocking.....	86
2.2.8	Monoclonal Antibody Labelling.....	87
2.2.9	Peroxidase Staining.....	88
B.	DNA Analysis.....	91
2.3	Materials.....	91
2.3.1	Bone Marrow and Blood Sources.....	91
2.3.2	Chemicals and Reagents.....	91
2.3.3	Probes/cDNA.....	91
2.3.4.	Preparation of Materials.....	92

2.4	Method.....	96
2.4.1	Aseptic Methods.....	96
2.4.2	Safety Precautions.....	96
2.4.3	Criteria for Sample Collection.....	96
2.4.4	Isolation of Single Bacterial Colonies.....	97
2.4.5	Alkaline Lysis Method.....	97
2.4.6	Restriction Enzyme Digestion of Plasmid.....	97
2.4.7	Extraction of Inserts.....	98
2.4.8	Extraction of Human DNA Samples.....	99
2.4.9	Restriction Enzyme Digestion.....	101
2.4.10	Agarose Gel Electrophoresis.....	101
2.4.11	Southern Blot Transfer.....	102
2.4.12	Labelling of DNA Fragments.....	104
2.4.13	Prehybridization.....	104
2.4.14	Hybridization.....	105
2.4.15	Washing the Blot.....	105
2.4.16	Autoradiography.....	106
2.4.17	Deprobing the Blot.....	106

### CHAPTER 3: RESULTS

3.1	Statistics.....	107
3.2	Immunophenotyping and Haematological Diagnosis.....	111
3.2.1	Phenotypic Subgroups.....	111
3.2.1.1	Acute Lymphoblastic Leukaemia.....	113
	Null-ALL.....	114
	C-ALL.....	116
	T-Cell.....	119
	B-ALL.....	124

3.2.1.2	Chronic Lymphocytic Leukaemia.....	127
3.2.1.3	Acute Myeloid Leukaemia.....	127
3.3	Clinical Presentation.....	130
3.4	DNA Analysis.....	136
3.4.1	Extraction of the cDNAs.....	136
3.4.2	Southern Blot.....	136
3.5	Gene Rearrangement Analysis.....	139
3.5.1	The Human C Delta Chain.....	139
3.5.2	The Human J Delta Probe.....	143
3.5.3	The Human Gamma Chain.....	149
3.5.4	The Human Beta Chain.....	154
3.5.5	The Human Alpha Chain, pY14.....	159
<b>CHAPTER 4: DISCUSSION</b>		
4.1	Statistics.....	165
4.2	Clinical Features.....	170
4.3	Immunophenotyping and Gene Analysis.....	172
<b>CHAPTER 5: CONCLUSION</b> .....		194
<b>CHAPTER 6: REFERENCES</b> .....		202

## LIST OF FIGURES

Figure	Page
<b>CHAPTER 1</b>	
1	The natural history of human B lymphocytes.....6
2	Rearrangement of the human kappa gene locus.....8
3	Genomic organization and restriction enzyme maps of the a)alpha, b)beta, c)gamma and d)delta loci .....17
4	The T Cell Receptor a)TCR polypeptides b)TCR:CD3 complex and receptor-ligand interaction.....22
5	Genomic organization of the murine T cell receptor loci.....32
<b>CHAPTER 3</b>	
6	Age, ethnic and sex distributions of T-ALL samples..125
7	Recombinant plasmid before and after restriction enzyme digestion.....137
8	Purified probes.....137
9a	Agarose gel after overnight electrophoresis of the digested DNA samples.....138
9b	The same gel after Southern transfer of the DNA samples.....138
10	The human C delta-chain (cDNA).....141
11	The human J delta probe.....148
12	The human gamma-chain (peripheral blood cDNA).....152
13	The human beta-chain.....158
14	The human alpha-chain (pY14).....151

## LIST OF TABLES

Table	Page
<b>CHAPTER 1</b>	
1	Characteristics of T cell Subsets.....13
2	Major phenotypic subgroups of childhood ALL.....61
3	Major phenotypic subgroups of adult ALL.....62
4	Distribution of ALL among different age groups.....62
<b>CHAPTER 2</b>	
5	Description of probe/cDNA.....93
<b>CHAPTER 3</b>	
6	Distribution of the total number of patients admitted to UHKL between September 1988 and September 1990...108
7	Approximate incidence of leukaemia among the ethnic groups and the adult and paediatric patients in UHKL.....110
8	Breakdown of the total number of ALL cases collected for immunophenotyping based on phenotypic subgroups.112
9	Percent distribution of ALLs phenotyped in UHKL....113
10	Surface Marker expression, haematological diagnosis and biological features of the Null-ALL subgroup...115
11	Surface marker expression, haematological diagnosis and biological features of the C-ALL subgroup.....117
12a	Surface marker expression and biological features of the T-cell subgroup.....121
12b	Haematological diagnosis of the T-cell subgroup....122
13	Surface marker expression, haematological diagnosis

	and biological features of the B-ALL subgroup.....	126
14	Surface marker expression, haematological diagnosis and biological features of the CLL subgroup.....	126
15	Surface marker expression, haematological diagnosis and biological features of the AML subgroup.....	128
16	Clinical features and FBC report of the Null-ALL, C-ALL and B-ALL subgroups.....	132
17	Clinical features and FBC report of the T-cell subgroup.....	133
18	Clinical features and FBC report of the AML subgroup.....	134
19	Delta, gamma, beta and alpha TCR gene rearrangement analysis of T cells.....	144
20	Delta, gamma, beta and alpha TCR gene rearrangement analysis of non-T cells.....	146

**CHAPTER 4**

21	Percentage of acute leukaemia in UHKL, phenotyped and reported.....	165
22	Percentage distribution of ALLs among phenotypic subgroups in UHKL and reported.....	166
23	Distribution of the number of immunophenotyped cases according to ethnic group, sex and age.....	169
24	Percentage of clinical features among the phenotypic subgroups.....	170